JPWO2021050948A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021050948A5 JPWO2021050948A5 JP2022516320A JP2022516320A JPWO2021050948A5 JP WO2021050948 A5 JPWO2021050948 A5 JP WO2021050948A5 JP 2022516320 A JP2022516320 A JP 2022516320A JP 2022516320 A JP2022516320 A JP 2022516320A JP WO2021050948 A5 JPWO2021050948 A5 JP WO2021050948A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- nucleic acid
- recombinant nucleic
- domain
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962899563P | 2019-09-12 | 2019-09-12 | |
| US62/899,563 | 2019-09-12 | ||
| US202062971682P | 2020-02-07 | 2020-02-07 | |
| US62/971,682 | 2020-02-07 | ||
| PCT/US2020/050503 WO2021050948A1 (en) | 2019-09-12 | 2020-09-11 | Compositions and methods for tcr reprogramming using fusion proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022548866A JP2022548866A (ja) | 2022-11-22 |
| JPWO2021050948A5 true JPWO2021050948A5 (ko) | 2023-09-20 |
Family
ID=74866684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022516320A Pending JP2022548866A (ja) | 2019-09-12 | 2020-09-11 | 融合タンパク質を用いたｔｃｒリプログラミングのための組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4028033A4 (ko) |
| JP (1) | JP2022548866A (ko) |
| KR (1) | KR20220078607A (ko) |
| CN (1) | CN114828862A (ko) |
| AU (1) | AU2020344628A1 (ko) |
| BR (1) | BR112022004458A2 (ko) |
| CA (1) | CA3154287A1 (ko) |
| IL (1) | IL291236A (ko) |
| MX (1) | MX2022002984A (ko) |
| WO (1) | WO2021050948A1 (ko) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023091420A2 (en) * | 2021-11-16 | 2023-05-25 | TCR2 Therapeutics Inc. | Compositions and methods for t cell engineering |
| WO2023133296A2 (en) * | 2022-01-07 | 2023-07-13 | Sorrento Therapeutics, Inc. | Engineered pd-l1-targeting gamma delta t cell receptors |
| WO2024039576A2 (en) * | 2022-08-19 | 2024-02-22 | Memorial Sloan-Kettering Cancer Center | T cell receptors targeting ras mutations and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9181527B2 (en) * | 2009-10-29 | 2015-11-10 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
| SG11201401030WA (en) * | 2011-10-28 | 2014-04-28 | Regeneron Pharma | Genetically modified t cell receptor mice |
| US11421013B2 (en) * | 2015-10-23 | 2022-08-23 | Eureka Therapeutics, Inc. | Antibody/T-cell receptor chimeric constructs and uses thereof |
| GB201604494D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers |
| WO2018067993A1 (en) * | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| JP7291396B2 (ja) * | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| CA3047999A1 (en) * | 2016-12-21 | 2018-06-28 | TCR2 Therapeutics Inc. | Engineered t cells for the treatment of cancer |
| WO2018232020A1 (en) * | 2017-06-13 | 2018-12-20 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| US11738047B2 (en) * | 2017-12-12 | 2023-08-29 | The Trustees Of The University Of Pennsylvania | Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof |
| WO2019133443A1 (en) * | 2017-12-28 | 2019-07-04 | Janux Therapeutics, Inc. | Modified t cell receptors |
| EP3765039A4 (en) * | 2018-03-09 | 2021-12-08 | TCR2 Therapeutics Inc. | COMPOSITIONS AND METHODS FOR REPROGRAMMING TCR USING FUSION PROTEINS |
-
2020
- 2020-09-11 JP JP2022516320A patent/JP2022548866A/ja active Pending
- 2020-09-11 CA CA3154287A patent/CA3154287A1/en active Pending
- 2020-09-11 KR KR1020227012166A patent/KR20220078607A/ko unknown
- 2020-09-11 AU AU2020344628A patent/AU2020344628A1/en not_active Abandoned
- 2020-09-11 BR BR112022004458A patent/BR112022004458A2/pt not_active Application Discontinuation
- 2020-09-11 WO PCT/US2020/050503 patent/WO2021050948A1/en unknown
- 2020-09-11 MX MX2022002984A patent/MX2022002984A/es unknown
- 2020-09-11 CN CN202080079086.5A patent/CN114828862A/zh active Pending
- 2020-09-11 EP EP20862242.3A patent/EP4028033A4/en not_active Withdrawn
-
2022
- 2022-03-09 IL IL291236A patent/IL291236A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11001621B1 (en) | Trifunctional T cell-antigen coupler and methods and uses thereof | |
| Zhang et al. | Engineering car-t cells | |
| Batlevi et al. | Novel immunotherapies in lymphoid malignancies | |
| JP7404279B2 (ja) | 様々な構築物最適化を備えたｔ細胞抗原カプラ | |
| US11878035B2 (en) | T cell-antigen coupler with various construct optimizations | |
| KR20210043623A (ko) | Hla-dr에 결합하는 키메라 항원 수용체 및 car-t 세포 | |
| Cruz-Ramos et al. | CAR-T cell and Personalized Medicine | |
| CN113454115A (zh) | 靶向唾液酸化路易斯a的嵌合抗原受体及其用途 | |
| TW201930589A (zh) | 表現特異性辨識人類間皮素之細胞表面分子、il-7、及ccl19之免疫活性細胞 | |
| CA3145223A1 (en) | Composition and method for adoptive immunotherapy | |
| JPWO2019173693A5 (ko) | ||
| AU2018367449B2 (en) | IL-33 secreting immunoresponsive cells and uses thereof | |
| JPWO2021050948A5 (ko) | ||
| Sasu et al. | T cell redirecting therapies for cancer treatment | |
| TWI790162B (zh) | 新穎t細胞受器及使用其之免疫治療 | |
| JP2023553049A (ja) | Ｃｄ１９＋、ｃｄ２０＋、若しくはｃｄ２２＋腫瘍又はｂ細胞由来の自己免疫疾患を治療するためのｃａｒ ｔ細胞 | |
| CA3198363A1 (en) | Methods and compositions comprising pd1 chimeric polypeptides | |
| WO2022150379A1 (en) | Nk cell engager molecules and methods of use | |
| JPWO2019226946A5 (ko) | ||
| KR20220040489A (ko) | T 세포 수용체 및 이의 사용 방법 | |
| Turazzi | BAFF RECEPTOR (BAFF-R) CAR-REDIRECTED T CELLS: A NOVEL TOOL TO TREAT HIGH RISK B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) |